Key result
Rivaroxaban fails to prevent surgically managed aortic bioprosthetic valve thrombosis in single case.
Why the study?
Bioprosthetic valve thrombosis is more common than previously thought, but cases occurring on direct oral anticoagulant therapy are not described.
Case Report (n=1)
Alerts clinicians to possible BPVT on rivaroxaban; leaves open optimal post-surgical anticoagulation regimens.
There is increasing evidence that bioprosthetic valve thrombosis (BPVT) is more common than previously thought. However, there are very few cases describing the occurrence of BPVT on therapeutic anticoagulation, and no previous cases are available stating the occurrence of BPVT on direct oral anticoagulant therapy. We describe the case of surgically managed aortic BPVT that was diagnosed while the patient was on rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Leatherby et al. (2018) conducted a case report in Bioprosthetic valve thrombosis (BPVT) (n=1). Rivaroxaban was evaluated on Bioprosthetic valve thrombosis. Rivaroxaban therapy did not prevent the development of aortic bioprosthetic valve thrombosis requiring surgical management in a single patient case.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: